Therefore, in view of high glomerular and tubular expressions of VEGF-A in physiologic circumstances and its upregulation in diabetes, we tested the hypothesis that inhibition of VEGF-A activity by the antiangiogenic drug endostatin prevents renal injury and the onset of early renal dysfunction in a streptozotocin-induced rat model of type 1 diabetes. This evidence concerns the gene VEGFA and diabetes mellitus.